lvrachЛечащий ВрачLechaschi Vrach1560-51752687-118110.51793/OS.2023.26.4.001lvrach-1057Research ArticleАЛЛЕРГОЛОГИЯALLERGOLOGYПреимущества эбастина с позиций клинической фармакологииBenefits of ebastine from the position of clinical pharmacologyhttps://orcid.org/0000-0001-9273-6864ИвкинД. Ю.IvkinD. Yu.

Ивкин Дмитрий Юрьевич - кандидат биологических наук, начальник центра экспериментальной фармакологии, доцент кафедры фармакологии и клинической фармакологии Санкт-Петербургский ГХУ; доцент кафедры органической химии РГПУ им. А. И. Герцена.

197022, Санкт-Петербург, ул. Профессора Попова, 14, лит. А; 191186, Санкт-Петербург, набережная реки Мойки, 48

Dmitry Yu. Ivkin - Cand. of Sci. (Biol.), Head of the Center for Experimental Pharmacology, Associate Professor of the Department of Pharmacology and Clinical Pharmacology St. Petersburg SCPU; Associate Professor of the Department of Organic Chemistry at the Federal State Budgetary Educational Institution of Higher Education A. I. Herzen RSPU.

14 lit. A Prof. Popov str., St. Petersburg, 197022; 48 Moika River Embankment, Saint Petersburg, 191186

dmitry.ivkin@pharminnotech.comhttps://orcid.org/0000-0003-2448-513XГришинаА. Ю.GrishinaA. Yu.

Гришина Анна Юрьевна - младший научный сотрудник центра экспериментальной фармакологии.

197022, Санкт-Петербург, ул. Профессора Попова, 14, лит. А

Anna Yu. Grishina - Junior Researcher, Center for Experimental Pharmacology.

14 lit. A Prof. Popov str., St. Petersburg, 197022

grishina.anna@pharminnotech.comhttps://orcid.org/0000-0002-7965-8061ПетроваА. Г.PetrovaA. G.

Петрова Алла Германовна - доктор медицинских наук, профессор, главный научный сотрудник лаборатории инфектологии и иммунопрофилактики в педиатрии.

664003, Иркутск, ул. Тимирязева, 16

Alla G. Petrova - Dr. of Sci. (Med.), Professor, Chief Researcher of the Laboratory of Infectology and Immunoprophylaxis in Pediatrics.

16 Timiryazeva str., Irkutsk, 664003

rudial75@gmail.comhttps://orcid.org/0000-0003-4196-0713МоскалеваЕ. В.MoskalevaE. V.

Москалева Екатерина Владимировна - кандидат медицинских наук, научный сотрудник лаборатории инфектологии и иммунопрофилактики в педиатрии.

664003, Иркутск, ул. Тимирязева, 16

Ekaterina V. Moskaleva - MD, Researcher of the Laboratory of Infectology and Immunoprophylaxis in Pediatrics.

16 Timiryazeva str., Irkutsk, 664003

mkatena@gmail.comhttps://orcid.org/0000-0003-4826-2416СелизароваН. О.SelizarovaN. O.

Селизарова Наталья Олеговна - кандидат медицинских наук, доцент кафедры фармакологии и клинической фармакологии.

197022, Санкт-Петербург, ул. Профессора Попова, 14, лит. А

Natalia O. Selizarova - MD, Associate Professor of the Department of Pharmacology and Clinical Pharmacology.

14 lit. A Prof. Popov str., St. Petersburg, 197022

natalia.selizarova@pharminnotech.comФедеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургский государственный химико-фармацевтический университет Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования Российский государственный педагогический университет имени А.И. ГерценаРоссияFederal State Budgetary Educational Institution of Higher Education St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education A. I. Herzen Russian State Pedagogical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургский государственный химико-фармацевтический университет Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian FederationRussian FederationФедеральное государственное бюджетное научное учреждение Научный центр проблем здоровья семьи и репродукции человекаРоссияFederal State Budgetary Scientific Institution Scientific Center for Family Health and Human ReproductionRussian Federation20231106202304716Copyright © Ивкин Д.Ю., Гришина А.Ю., Петрова А.Г., Москалева Е.В., Селизарова Н.О., 20232023Ивкин Д.Ю., Гришина А.Ю., Петрова А.Г., Москалева Е.В., Селизарова Н.О.Ivkin D.Y., Grishina A.Y., Petrova A.G., Moskaleva E.V., Selizarova N.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/1057

В статье рассмотрены данные о фармакокинетике, фармакодинамике, эффективности и безопасности эбастина, представлены обзоры наиболее значимых клинических исследований при лечении аллергических заболеваний (аллергический ринит, крапивница) и сравнительных исследований с другими антигистаминными препаратами, имеющимися в арсенале современного практического врача. Данные множественных доклинических и клинических исследований, представленные в отечественных и зарубежных источниках, позволяют широко продемонстрировать его эффективность и безопасность. Эбастин характеризуется как препарат с достаточно высоким профилем безопасности из-за отсутствия седативного, атропиноподобного и кардиотропного эффектов, тахифилаксии и взаимодействия с другими лекарственными средствами, а также влияния на способность управления автотранспортом и сложными механизмами. Фармакокинетические свойства эбастина характеризуют препарат как высокоселективный Н1-гистаминоблокатор длительного действия, который можно принимать вне зависимости от приема пищи. Высокая терапевтическая эффективность эбастина при лечении различных аллергических заболеваний и состояний подтверждена многочисленными клиническими исследованиями. В том числе рассмотрена эффективность препарата при длительных курсах терапии: эбастин при приеме в течение 1 года сохраняет свою антигистаминную активность, что делает возможным назначение препарата в течение 3-12 месяцев. Антигистаминный и противовоспалительный эффекты эбастина позволяют купировать основные симптомы аллергии, а также першение в горле, приступы кашля, нарушения обоняния и шелушение кожи. Таким образом, антигистаминный препарат эбастин обладает фармакологическими характеристиками с высокой степенью соответствия требованиям к идеальному антигистаминному препарату.

The article reviews data on pharmacokinetics, pharmacodynamics, efficacy and safety of ebastine, presents reviews of the most significant clinical trials in the treatment of allergic diseases (allergic rhinitis, urticaria) and comparative studies with other antihistamine drugs available in the arsenal of a modern practical doctor. Data of multiple preclinical and clinical trials presented in domestic and foreign sources allow to demonstrate its effectiveness and safety widely. Ebastin is characterized as medicine with high enough safety profile due to absence of sedative, atropine-like and cardiotropic effects, absence of tachyphylaxis and interaction with other medicines, absence of influence on ability to drive motor transport and complicated mechanisms. Pharmacokinetic properties of ebastine characterize the drug as a highly selective H1-histamine-blocker of long action, which can be taken regardless of meals. High therapeutic efficacy of ebastine in treatment of various allergic diseases and conditions has been confirmed by numerous clinical studies. Including the effectiveness of the drug in long-term courses of therapy, ebastin when taken for 1 year retains its antihistamine activity, which makes it possible to prescribe the drug for 3-12 months. Antihistamine and anti-inflammatory effects of ebastine allow to stop the main symptoms of allergy, as well as throat fart, coughing fits, olfactory disorders and skin peeling. Thus, the antihistamine drug ebastine has pharmacological characteristics with a high degree of compliance with the requirements for an "ideal" antihistamine drug.

аллергические заболеванияантигистаминные препаратыгистаминэбастинкаребастинэффективностьбезопасностьантигистаминные препараты второго поколениягиперчувствительностьаллергический ринитallergic diseasesantihistamineshistamineebastinekarebastineefficacysafetysecond generation antihistamineshypersensitivityallergic rhinitisReferencesKawauchi H., Yanai K., et al. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties // Int J Mol Sci. 2019; 20 (1): 213.Kawauchi H., Yanai K., et al. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties // Int J Mol Sci. 2019; 20 (1): 213.Paśko P., Rodacki T., et al. Second generation H1 – antihistamines interaction with food and alcohol – A systematic review // Biomedicine & Pharmacotherapy. 2017; 93: 27-39.Paśko P., Rodacki T., et al. Second generation H1 – antihistamines interaction with food and alcohol – A systematic review // Biomedicine & Pharmacotherapy. 2017; 93: 27-39.Емельянов А. В., Кочергин Н. Г., Горячкина Л. А. К 100-летию открытия гистамина. История и современные подходы к клиническому применению антигистаминных препаратов // Клиническая дерматология и венерология. 2010; 8 (4): 62-70.Yemel'yanov A. V., Kochergin N. G., Goryachkina L. A. To the 100th anniversary of the discovery of histamine. History and modern approaches to the clinical use of antihistamines // Klinicheskaya dermatologiya i venerologiya. 2010; 8 (4): 62-70Bousquet J., Bindslev-Jensen C., Canonica G. W., The ARIA/EAACI criteria for anti#histamines: an assessment of the efficacy, safety and pharmacology of desloratadine // Allergy. 2004; 59 (suppl. 77): 4-16.Bousquet J., Bindslev-Jensen C., Canonica G. W., The ARIA/EAACI criteria for anti#histamines: an assessment of the efficacy, safety and pharmacology of desloratadine // Allergy. 2004; 59 (suppl. 77): 4-16.Bousquet J., Khaltaev N., Cruz A., et al. Allergic rhinitis and its impact on asthma (ARIA 2008) // Allergy. 2008: 63 (Supple 86). 9-160.Bousquet J., Khaltaev N., Cruz A., et al. Allergic rhinitis and its impact on asthma (ARIA 2008) // Allergy. 2008: 63 (Supple 86). 9-160.Bousquet J. et al. Requirements for medications commonly used in the treatment of allergic rhinitis // Allergy. 2003; 58: 192.Bousquet J. et al. Requirements for medications commonly used in the treatment of allergic rhinitis // Allergy. 2003; 58: 192.Llupià J., Gras J., Llenas J. Comparative antiallergic effects of secondgeneration H1-antihistamines ebastine, cetirizine and loratadine in preclinical models // Arzneimittelforschung. 2003; 53 (2): 93-97.Llupià J., Gras J., Llenas J. Comparative antiallergic effects of secondgeneration H1-antihistamines ebastine, cetirizine and loratadine in preclinical models // Arzneimittelforschung. 2003; 53 (2): 93-97.Gispert J. et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges // Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 2002; 3 (89): 259-264.Gispert J. et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges // Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 2002; 3 (89): 259-264.A double blind, randomized, unicentric, crossover and placebo-controlled clinical trial to evaluate the inhibitory effect of ebastine 20 mg (oral lyophilisate) and desloratadine 5 mg on the histamine induced skin reaction in healthy volonteers. Almirall Prodesfarma, S.A., 2005.A double blind, randomized, unicentric, crossover and placebo-controlled clinical trial to evaluate the inhibitory effect of ebastine 20 mg (oral lyophilisate) and desloratadine 5 mg on the histamine induced skin reaction in healthy volonteers. Almirall Prodesfarma, S.A., 2005.A double blind, randomized, unicentric, crossover and placebo-controlled clinical trial to evaluate the inhibitory effect of ebastine 10 mg (oral lyophilisate) and desloratadine 5 mg on the histamine induced skin reaction in healthy volonteers. Almirall Prodesfarma, S.A., 2006.A double blind, randomized, unicentric, crossover and placebo-controlled clinical trial to evaluate the inhibitory effect of ebastine 10 mg (oral lyophilisate) and desloratadine 5 mg on the histamine induced skin reaction in healthy volonteers. Almirall Prodesfarma, S.A., 2006.Ключарова А. Р. Сравнительная оценка эффективности антигистаминных препаратов второго поколения в терапии хронической крапивницы с учетом изменений когнитивных функций пациента. Автореферат … дисс. к.м. н. М., 2014. 23 с.Klyucharova A. R. Comparative evaluation of the effectiveness of secondgeneration antihistamines in the treatment of chronic urticaria, taking into account changes in the patient's cognitive functions. Avtoreferat … diss. k.m. n. M., 2014. P. 23.]Antonijoan R. M., Garcнa-Gea C., Puntes M., Valle M., Esbri R., Fortea J., et al. A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction histamine in healthy adults // Clin Drug Investig. 2007; 27: 453-461.Antonijoan R. M., Garcнa-Gea C., Puntes M., Valle M., Esbri R., Fortea J., et al. A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction histamine in healthy adults // Clin Drug Investig. 2007; 27: 453-461.Nelson H. S., Bucher B., Buchmeier A., Oppenheimer J., Garcia J. Suppression of the skin reaction to histamine by ebastine // Ann Allergy Asthma Immunol. 1995; 74: 442-447.Nelson H. S., Bucher B., Buchmeier A., Oppenheimer J., Garcia J. Suppression of the skin reaction to histamine by ebastine // Ann Allergy Asthma Immunol. 1995; 74: 442-447.Vincent J., Liminana R., Meredith P. A., Reid J. L. The pharmacokinetics, antihistamine and concentration effect relationship of ebastine in healthy subjects // Br J Clin Pharmacol. 1988; 26: 497-502.Vincent J., Liminana R., Meredith P. A., Reid J. L. The pharmacokinetics, antihistamine and concentration effect relationship of ebastine in healthy subjects // Br J Clin Pharmacol. 1988; 26: 497-502.Van Steekelenburg J., Clement P. A., Beel M. H. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests // Allergy. 2002; 57: 346-350.Van Steekelenburg J., Clement P. A., Beel M. H. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests // Allergy. 2002; 57: 346-350.Frossard N., Vital-Durand D., Mounedji N., Valleteau A. Duration of the antihistaminic effect after discontinuation of ebastine // Allergy. 2001; 56: 553-557.Frossard N., Vital-Durand D., Mounedji N., Valleteau A. Duration of the antihistaminic effect after discontinuation of ebastine // Allergy. 2001; 56: 553-557.Frossard N., Melac M., Benabdesselam O., Pauli G. Consistency of the efficacy of cetirizine and ebastine on skin reactivity // Ann Allergy Asthma Immunol. 1998; 80: 61-65.Frossard N., Melac M., Benabdesselam O., Pauli G. Consistency of the efficacy of cetirizine and ebastine on skin reactivity // Ann Allergy Asthma Immunol. 1998; 80: 61-65.Wood-Baker R., Holgate S. T. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholineinduced bronchoconstriction in patients with asthma // Agents Actions. 1990; 30: 284-286.Wood-Baker R., Holgate S. T. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholineinduced bronchoconstriction in patients with asthma // Agents Actions. 1990; 30: 284-286.Campbell A., Michel F. B., Bremard-Oury C., Crampette L., Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect // Drugs. 1996; 52 Suppl 1: 15-9.Campbell A., Michel F. B., Bremard-Oury C., Crampette L., Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect // Drugs. 1996; 52 Suppl 1: 15-9.Hurst M., Spencer C. M. Ebastine — an update of its use in allergic disorders // Drugs. 2000; 59 (4): 981-1006.Hurst M., Spencer C. M. Ebastine — an update of its use in allergic disorders // Drugs. 2000; 59 (4): 981-1006.Van Cauwenberge P., de Belder T., Sys L. A review of the second-generation antihistamine ebastine for the treatment of allergic disorders // Expert Opin. Pharmacother. 2004; 5: 1807-1813.Van Cauwenberge P., de Belder T., Sys L. A review of the second-generation antihistamine ebastine for the treatment of allergic disorders // Expert Opin. Pharmacother. 2004; 5: 1807-1813.Frank H. Jr., Gillen M., Rohatagi S. S., Lim J., George G., Ebastine Study Group. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis // J Clin Pharmacol. 2002; 42: 1097-104.Frank H. Jr., Gillen M., Rohatagi S. S., Lim J., George G., Ebastine Study Group. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis // J Clin Pharmacol. 2002; 42: 1097-104.Pentikis H. S., Huang M. Y., Dorr M. B., Heald D. L. The effect of food on the bioavailability of ebastine // Am J Ther. 1997; 4: 80-84.Pentikis H. S., Huang M. Y., Dorr M. B., Heald D. L. The effect of food on the bioavailability of ebastine // Am J Ther. 1997; 4: 80-84.Yamaguchi T., Hashizume T., Matsuda M., Sakashita M., Fujii T., Sekine Y., et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects // Arzneimittelforschung. 1994; 44: 59-64.Yamaguchi T., Hashizume T., Matsuda M., Sakashita M., Fujii T., Sekine Y., et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects // Arzneimittelforschung. 1994; 44: 59-64.Gervasini G., Vizcaino S., Carrillo J. A., Caballero M. J., Benitez J. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study // Br. J. Clin. Pharmacol. 2006; 62: 177-186.Gervasini G., Vizcaino S., Carrillo J. A., Caballero M. J., Benitez J. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study // Br. J. Clin. Pharmacol. 2006; 62: 177-186.Mattila M. J., Aranko K., Kuitunen T. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine // Br J Clin Pharmacol. 1993; 35: 272-277.Mattila M. J., Aranko K., Kuitunen T. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine // Br J Clin Pharmacol. 1993; 35: 272-277.Simons F. E., Simons K. J. Histamine and H1-antihistamines: celebrating a century of progress // J Allergy Clin Immunol. 2011; 128 (6): 1139-1150.Simons F. E., Simons K. J. Histamine and H1-antihistamines: celebrating a century of progress // J Allergy Clin Immunol. 2011; 128 (6): 1139-1150.Ebastin. Product Monograph. 2001 Almirall Prodesfarma S.A.Ebastin. Product Monograph. 2001 Almirall Prodesfarma S.A.Study M/09020/02 Almirall Prodesfarma. Data on file.Study M/09020/02 Almirall Prodesfarma. Data on file.Roberts D. J. A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist // Drugs. 1996; 52 Suppl 1: 8-14.Roberts D. J. A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist // Drugs. 1996; 52 Suppl 1: 8-14.Goyal V. et al. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria // J. Clin. Diagn. Res. JCDR. 2017; 3 (11): WC06-WC09.Goyal V. et al. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria // J. Clin. Diagn. Res. JCDR. 2017; 3 (11): WC06-WC09.Tashiro M. et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography // J. Clin. Pharmacol. 2004; 8 (44): 890-900.Tashiro M. et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography // J. Clin. Pharmacol. 2004; 8 (44): 890-900.Sánchez J., Zakzuk J., Cardona R. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine- Induced Wheal // J. Investig. Allergol. Clin. Immunol. 2016; 3 (26): 177-184.Sánchez J., Zakzuk J., Cardona R. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine- Induced Wheal // J. Investig. Allergol. Clin. Immunol. 2016; 3 (26): 177-184.Vincent J., Sumner D. J., Reid J. L. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects // Br J Clin Pharmacol. 1988; 26 (5): 503-508. DOI: 10.1111/j.1365-2125.Vincent J., Sumner D. J., Reid J. L. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects // Br J Clin Pharmacol. 1988; 26 (5): 503-508. DOI: 10.1111/j.1365-2125.Berts D. J., Gispert J. The non-cardiac systemic side-effects of antihistamines: ebastine // Clin. Exp. Allergy. 1999; (Suppl. 3): 151-155.Berts D. J., Gispert J. The non-cardiac systemic side-effects of antihistamines: ebastine // Clin. Exp. Allergy. 1999; (Suppl. 3): 151-155.HINDMARCH, Shamsi Z. The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers // Carr. Med. Res. Opin. 2001; 17: 273-281.HINDMARCH, Shamsi Z. The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers // Carr. Med. Res. Opin. 2001; 17: 273-281.Mattila M., Kuitunen T., Plétan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects // Eur J Clin Pharmacol. 1992; 43: 179-184.Mattila M., Kuitunen T., Plétan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects // Eur J Clin Pharmacol. 1992; 43: 179-184.Brookhuis K., de Vries G., de Waard D. Acute and subchronic effects of the H1 receptor antagonist ebastine in 10, 20 and 30 mg dose and triprolidine 10 mg on car driving performance // Br. J. Clin. Pharmacy. 1993; 36: 67-70.Brookhuis K., de Vries G., de Waard D. Acute and subchronic effects of the H1 receptor antagonist ebastine in 10, 20 and 30 mg dose and triprolidine 10 mg on car driving performance // Br. J. Clin. Pharmacy. 1993; 36: 67-70.Tagawa M., Kano M., Okamura N., et al. Differential cognitive effects of ebastine ad (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration // Br. J. Clin. Pharmacy. 2002; 53: 296-304.Tagawa M., Kano M., Okamura N., et al. Differential cognitive effects of ebastine ad (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration // Br. J. Clin. Pharmacy. 2002; 53: 296-304.Gehanno P., Bremard-Oury C., Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults // Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 1996; 6 (76): 507-512.Gehanno P., Bremard-Oury C., Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults // Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 1996; 6 (76): 507-512.Nachtigall. Henry B. Clinical evaluation of Diphenylpyraline // J. of Allergy. 1956; 1 (27): 75-77.Nachtigall. Henry B. Clinical evaluation of Diphenylpyraline // J. of Allergy. 1956; 1 (27): 75-77.Puhakka H., Rantanen T., Virolainen E. Diphenylpyraline (Lergobine)in treatment of patients suffering from allergic and vasomotor rhinitis // J. Int. Med. Res. 1977; 1 (5): 37-41.Puhakka H., Rantanen T., Virolainen E. Diphenylpyraline (Lergobine)in treatment of patients suffering from allergic and vasomotor rhinitis // J. Int. Med. Res. 1977; 1 (5): 37-41.Гущин И. С., Данилычева И. В. Эбастин. Обоснованный выбор // Российский аллергологический журнал. 2017; 4-5 (14): 89-97.Гущин И. С., Данилычева И. В. Эбастин. Обоснованный выбор // Российский аллергологический журнал. 2017; 4-5 (14): 89-97.Гущин И. С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт, 1998. 252 с.Гущин И. С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт, 1998. 252 с.Чеча О. А., Бунятян Н. Д., Тенцова А. И. Стереоспецифичность лекарственных препаратов – один из факторов эффективности и безопасности лекарственных средств // Фармация. 2012; 8: 40-43.Чеча О. А., Бунятян Н. Д., Тенцова А. И. Стереоспецифичность лекарственных препаратов – один из факторов эффективности и безопасности лекарственных средств // Фармация. 2012; 8: 40-43.Смирнова И. Г., Гильдеева Г. Н., Кукес В. Г. Оптическая изомерия и биологическая активность лекарственных средств // Вестник Московского университета. Серия 2: Химия. 2012; 3 (53): 147-156.Смирнова И. Г., Гильдеева Г. Н., Кукес В. Г. Оптическая изомерия и биологическая активность лекарственных средств // Вестник Московского университета. Серия 2: Химия. 2012; 3 (53): 147-156.Vincent J., Sumner D. J., Reid J. L. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects // Br J Clin Pharmac. 1988; 26: 503-508.Vincent J., Sumner D. J., Reid J. L. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects // Br J Clin Pharmac. 1988; 26: 503-508.Robert M., Llorens M., García E., Luria X. Эффективность и переносимость эбастина в дозировке 10 мг в комбинации с деконгестивной терапией для облегчения симптомов простуды (ассоциированного ринита) // 2013; 1 (11): 35-40.Robert M., Llorens M., García E., Luria X. Efficacy and tolerability of ebastine 10 mg in combination with decongestive therapy for the reliefof symptoms of the common cold (associated rhinitis) // 2013; 1 (11): 35-40.Демидова О. А., Ших Е. В., Исмагилов А. Д., Сизова Ж. М. Клиникофармакологические аспекты безопасности применения лекарственных средств, вызывающих удлинение интервала QT // Безопасность и риск фармакотерапии. 2017; 3 (5): 117-125. EDN ZGRTVV.Demidova O. A., Shikh Ye. V., Ismagilov A. D., Sizova Zh. M. Clinical and pharmacological aspects of the safety of the use of drugs that cause QT prolongation // Bezopasnost' i risk farmakoterapii. 2017; 3 (5): 117-125. EDN ZGRTVV.Гуськова Т. А. Лекарственная токсикология и безопасность лекарственных средств / IV Съезд токсикологов России: Сборник трудов, Москва, 06-08 ноября 2013 года / Под ред. Г. Г. Онищенко и Б. А. Курляндский. М.: Российский регистр потенциально опасных химических и биологических веществ, 2013. С. 14-15.Gus'kova T. A. Drug toxicology and drug safety / IV S"yezd toksikologov Rossii: Sbornik trudov, Moskva, 06-08 noyabrya 2013 goda / Pod red. G. G. Onishchenko i B. A. Kurlyandskiy. M.: Rossiyskiy registr potentsial'no opasnykh khimicheskikh i biologicheskikh veshchestv, 2013. P. 14-15.Yakuo I., Ishii K., Seto Y., Imano K., Takeyama K., Nakamura H., Karasawa T. Pharmacological study of ebastine, a novel histamine H1-receptor antagonist // Nihon Yakurigaku Zasshi. 1994; 103 (3): 121-35. Japanese. DOI: 10.1254/fpj.103.121. PMID: 7511558.Yakuo I., Ishii K., Seto Y., Imano K., Takeyama K., Nakamura H., Karasawa T. Pharmacological study of ebastine, a novel histamine H1-receptor antagonist // Nihon Yakurigaku Zasshi. 1994; 103 (3): 121-35. Japanese. DOI: 10.1254/fpj.103.121. PMID: 7511558.Cohen B., Gehanno P. Comparison of the efficacy of ebastine 10 mg and 20 mg once daily with that of cetirizine 10 mg once daily in adults with seasonal allergic rhinitis. A multicentre double-blind study // Drugs. 1996; 52: Suppl. 1: 26-29.Cohen B., Gehanno P. Comparison of the efficacy of ebastine 10 mg and 20 mg once daily with that of cetirizine 10 mg once daily in adults with seasonal allergic rhinitis. A multicentre double-blind study // Drugs. 1996; 52: Suppl. 1: 26-29.De Molina M., Cadahia A., Cano L., Sanz A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis // Drug Investig. 1989; 1: 40-46.De Molina M., Cadahia A., Cano L., Sanz A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis // Drug Investig. 1989; 1: 40-46.Ratner P. H., Lim J. C., Georges G. C. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis // J Allergy Clin Immunol. 2000; 105 (6): 1101-1107.Ratner P. H., Lim J. C., Georges G. C. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis // J Allergy Clin Immunol. 2000; 105 (6): 1101-1107.Benavente V., Eseverri J. L., Botey J., Marin A. Ebastine: treatment of perennial rhinitis in the child // Allerg Immunol (Paris). 1996; 28 (8): 277-281.Benavente V., Eseverri J. L., Botey J., Marin A. Ebastine: treatment of perennial rhinitis in the child // Allerg Immunol (Paris). 1996; 28 (8): 277-281.Bousquet J., Gaudano E. M., Palma Carlos A. G., Staudinger H. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis // Multicentre Study Group. Allergy. 1999; 54 (6): 562-568.Bousquet J., Gaudano E. M., Palma Carlos A. G., Staudinger H. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis // Multicentre Study Group. Allergy. 1999; 54 (6): 562-568.Davies R. J. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with pernnial allergic rhinitis // Clin Drug Investig 1998; 16: 413-420.Davies R. J. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with pernnial allergic rhinitis // Clin Drug Investig 1998; 16: 413-420.Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticarial in adults // Drugs. 1996; 52: Suppl. 1: 30-34.Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticarial in adults // Drugs. 1996; 52: Suppl. 1: 30-34.Horiguchi T., Tachikawa S., Kasahara J., et al. Влияние эбастина на концентрации катионного белка эозинофилов в сыворотке у пациентов с бронхиальной астмой // Медицинский совет. 2013; 4 (11): 36-40.Horiguchi T., Tachikawa S., Kasahara J., et al. Effect of ebastine on serum cationic protein concentrations of eosinophils in patients with bronchial asthma // Meditsinskiy sovet. 2013; 4 (11): 36-40.]Holgate S. T., Canonica G. W., Simons F. E. R., et al. Consensus group on new generation antihistamines (CONGA): present status and recommendations // Clin. Exp. Allergy. 2003; 33: 1305-1324.Holgate S. T., Canonica G. W., Simons F. E. R., et al. Consensus group on new generation antihistamines (CONGA): present status and recommendations // Clin. Exp. Allergy. 2003; 33: 1305-1324.Reunala T., Brummer-Korvenkontio H., Petman L., Palosuo T., Sarna S. Effect of ebastine on mosquito bites // Acta Derm Venereol. 1997; 77 (4): 315-316. DOI: 10.2340/0001555577315316. PMID: 9228228.Reunala T., Brummer-Korvenkontio H., Petman L., Palosuo T., Sarna S. Effect of ebastine on mosquito bites // Acta Derm Venereol. 1997; 77 (4): 315-316. DOI: 10.2340/0001555577315316. PMID: 9228228.Karppinen A., Petman L., Jekunen A., Kautiainen H., Vaalasti A., Reunala T. Treatment of mosquito bites with ebastine: a field trial // Acta Derm Venereol. 2000; 80 (2): 114-116. PMID: 10877131.Karppinen A., Petman L., Jekunen A., Kautiainen H., Vaalasti A., Reunala T. Treatment of mosquito bites with ebastine: a field trial // Acta Derm Venereol. 2000; 80 (2): 114-116. PMID: 10877131.Karppinen A., Kautiainen H., Petman L., Burri P., Reunala T. Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. // Allergy. 2002; 57 (6): 534-537. DOI: 10.1034/j.1398-9995.2002.13201.x. PMID: 12028119.Karppinen A., Kautiainen H., Petman L., Burri P., Reunala T. Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. // Allergy. 2002; 57 (6): 534-537. DOI: 10.1034/j.1398-9995.2002.13201.x. PMID: 12028119.

The authors declare that there are no conflicts of interest present.